BioN­Tech and Pfiz­er an­nounce $225M shin­gles vac­cine project, of­fer­ing mR­NA chal­lenger to Glax­o­SmithK­line's Shin­grix

One of the biggest sto­ry­lines of biotech’s next half-decade will be where Mod­er­na, BioN­Tech and their grow­ing list of ri­vals push the mR­NA tech­nol­o­gy that’s al­ready changed the world.

BioN­Tech and Pfiz­er gave part of the an­swer Wednes­day, an­nounc­ing a new part­ner­ship to co-de­vel­op an mR­NA-based shin­gles vac­cine. The can­di­date will be ready for ear­ly-stage tri­als in the sec­ond half of 2022, the com­pa­nies said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER